yutiq
Generic: fluocinolone acetonide intravitreal implant·Brand: Yutiq
yutiq: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ALIMERA SCIENCES INC (ALIM) | Approved |
FDA Decisions
Approval1. INDICATIONS AND USAGE YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ contains a corticosteroid and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. ( 1 )(ALIM)
Frequently asked questions
Who is developing yutiq?
yutiq is being developed by ALIMERA SCIENCES INC.
What is yutiq's latest FDA decision?
The most recent tracked FDA decision for yutiq is Approval for 1. INDICATIONS AND USAGE YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ contains a corticosteroid and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. ( 1 ), dated October 12, 2018.
Get deeper analysis on yutiq
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis